FLT3 and acute myeloid leukemia: In a combined analysis of 743 patients with CN-AML treated in SWOG and MCR/NCRI trials, Ostronoff et al. demonstrated that NPM1MT, FLT3-ITDNEG, and CN-AML patients in the 55–65-year age group had a better two-year OS as compared to those without this genotype (65% vs. 40%, p < 0.001).